
    
      Phase III randomized controlled trial on men and women with MetS to test the hypothesis that
      comprehensive life-style changes and/or metformin treatment prevent ArCD.

      Design:

      2x2 factorial: 2,000 volunteers will be randomized in four equal groups of 500 each, and
      allocated to the following treatments: METFORMIN (1700MG/DAY) + ACTIVE LIFESTYLE INTERVENTION
      PLACEBO + ACTIVE LIFESTYLE INTERVENTION METFORMIN (1700 mg/day) alone PLACEBO alone The
      metformin /placebo component of the study will be double blind.
    
  